{"title":"Pharmacists in California HMOs gain expanded role.","authors":"A S Wittenburg","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":7452,"journal":{"name":"American journal of hospital pharmacy","volume":"51 23","pages":"2890, 2893"},"PeriodicalIF":0.0,"publicationDate":"1994-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18879056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
New York State's prescription drug benefits program is described. The Empire Plan, a part of the New York State Health Insurance Program, includes a prescription drug benefits program. The prescription drug program began in 1986 and covers more than 700,000 people. In 1988 the state started a therapeutic drug-use-evaluation (DUE) program in correct with the supplier, Health Information Designs, a subsidiary of ValueRx Pharmacy Program. In 1991 the partnership with ValueRx was expanded to include patient profilling and physician education. In 1993 the state implemented a prior-authorization program for certain high-technology drugs, also administered by ValueRx. New York's public work force is heavily unionized, and the unions have been deeply involved in program design and vendor selection. Program participants have access to a large network of community pharmacies. The program also provides mail-order service. Quality is at the center of the state's and the unions' prescription drug program philosophy. Saving money is also a major objective; savings totaling $19.5 million were realized from 1988 through 1993 under the partnership between the state and ValueRx. The Empire Plan's prescription drug benefits program is building quality and saving money by integrating DUE, prior authorization, education, community pharmacy, and mail-order service.
{"title":"Overview of the New York State program for prescription drug benefits.","authors":"E L Lennard, P E Feinberg","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>New York State's prescription drug benefits program is described. The Empire Plan, a part of the New York State Health Insurance Program, includes a prescription drug benefits program. The prescription drug program began in 1986 and covers more than 700,000 people. In 1988 the state started a therapeutic drug-use-evaluation (DUE) program in correct with the supplier, Health Information Designs, a subsidiary of ValueRx Pharmacy Program. In 1991 the partnership with ValueRx was expanded to include patient profilling and physician education. In 1993 the state implemented a prior-authorization program for certain high-technology drugs, also administered by ValueRx. New York's public work force is heavily unionized, and the unions have been deeply involved in program design and vendor selection. Program participants have access to a large network of community pharmacies. The program also provides mail-order service. Quality is at the center of the state's and the unions' prescription drug program philosophy. Saving money is also a major objective; savings totaling $19.5 million were realized from 1988 through 1993 under the partnership between the state and ValueRx. The Empire Plan's prescription drug benefits program is building quality and saving money by integrating DUE, prior authorization, education, community pharmacy, and mail-order service.</p>","PeriodicalId":7452,"journal":{"name":"American journal of hospital pharmacy","volume":"51 23","pages":"2944-8"},"PeriodicalIF":0.0,"publicationDate":"1994-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18879061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Stability of mesalamine in rectal suspension diluted with distilled water.","authors":"L. M. Henderson, C. Johnson, R. Berardi","doi":"10.1093/AJHP/51.23.2955","DOIUrl":"https://doi.org/10.1093/AJHP/51.23.2955","url":null,"abstract":"","PeriodicalId":7452,"journal":{"name":"American journal of hospital pharmacy","volume":"144 1","pages":"2955-7"},"PeriodicalIF":0.0,"publicationDate":"1994-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79920687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Pharmacists in California HMOs gain expanded role.","authors":"A. S. Wittenburg","doi":"10.1093/AJHP/51.23.2890","DOIUrl":"https://doi.org/10.1093/AJHP/51.23.2890","url":null,"abstract":"","PeriodicalId":7452,"journal":{"name":"American journal of hospital pharmacy","volume":"134 1","pages":"2890, 2893"},"PeriodicalIF":0.0,"publicationDate":"1994-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80296891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"National health care reform, Part 1: Why it fizzled.","authors":"W. A. Zellmer","doi":"10.1093/AJHP/51.23.3008","DOIUrl":"https://doi.org/10.1093/AJHP/51.23.3008","url":null,"abstract":"","PeriodicalId":7452,"journal":{"name":"American journal of hospital pharmacy","volume":"17 7","pages":"3008"},"PeriodicalIF":0.0,"publicationDate":"1994-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91440006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Delaware State Society helps mold law on nurse prescribing.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":7452,"journal":{"name":"American journal of hospital pharmacy","volume":"51 23","pages":"2898"},"PeriodicalIF":0.0,"publicationDate":"1994-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18879057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Information on drop size needs to be eyed closely.","authors":"M A Weiss, J R Hendrickson","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":7452,"journal":{"name":"American journal of hospital pharmacy","volume":"51 23","pages":"2969-70"},"PeriodicalIF":0.0,"publicationDate":"1994-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18879069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
E. Morales, S. Spinler, M. Wilson, M. Chin, E. Jozefiak
{"title":"Criteria for use of hypolipidemic agents in adults.","authors":"E. Morales, S. Spinler, M. Wilson, M. Chin, E. Jozefiak","doi":"10.1093/AJHP/51.22.2837","DOIUrl":"https://doi.org/10.1093/AJHP/51.22.2837","url":null,"abstract":"","PeriodicalId":7452,"journal":{"name":"American journal of hospital pharmacy","volume":"48 1","pages":"2837-41"},"PeriodicalIF":0.0,"publicationDate":"1994-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80384124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The compatibility of paclitaxel injection vehicle with a variety of i.v. administration and extension sets was studied in terms of the amount of diethylhexyl phthalate (DEHP) leached from the sets. Test solutions of paclitaxel injection vehicle corresponding to paclitaxel injection 0.3 and 1.2 mg/mL were prepared in polyolefin bags of 5% dextrose injection. The solutions were delivered in triplicate over 24 hours through 26 models of administration sets and 24 models of extension sets and collected in glass containers. Portions were removed after delivery and analyzed in duplicate for DEHP concentration by high-performance liquid chromatography. All the extension sets were compatible with paclitaxel injection vehicle. Most of the administration sets were also compatible. However, two administration sets were incompatible with paclitaxel vehicle corresponding to either drug concentration, and five sets were incompatible with the vehicle simulating the high (1.2-mg/mL) concentration. Some of the incompatible sets were labeled as not containing polyvinyl chloride (PVC). Solutions of paclitaxel vehicle leached DEHP from administration sets containing PVC and from some sets labeled as not containing PVC.
{"title":"Compatibility of paclitaxel injection vehicle with intravenous administration and extension sets.","authors":"L. Trissel, Q. Xu, J. Kwan, J. F. Martínez","doi":"10.1093/AJHP/51.22.2804","DOIUrl":"https://doi.org/10.1093/AJHP/51.22.2804","url":null,"abstract":"The compatibility of paclitaxel injection vehicle with a variety of i.v. administration and extension sets was studied in terms of the amount of diethylhexyl phthalate (DEHP) leached from the sets. Test solutions of paclitaxel injection vehicle corresponding to paclitaxel injection 0.3 and 1.2 mg/mL were prepared in polyolefin bags of 5% dextrose injection. The solutions were delivered in triplicate over 24 hours through 26 models of administration sets and 24 models of extension sets and collected in glass containers. Portions were removed after delivery and analyzed in duplicate for DEHP concentration by high-performance liquid chromatography. All the extension sets were compatible with paclitaxel injection vehicle. Most of the administration sets were also compatible. However, two administration sets were incompatible with paclitaxel vehicle corresponding to either drug concentration, and five sets were incompatible with the vehicle simulating the high (1.2-mg/mL) concentration. Some of the incompatible sets were labeled as not containing polyvinyl chloride (PVC). Solutions of paclitaxel vehicle leached DEHP from administration sets containing PVC and from some sets labeled as not containing PVC.","PeriodicalId":7452,"journal":{"name":"American journal of hospital pharmacy","volume":"4 1","pages":"2804-10"},"PeriodicalIF":0.0,"publicationDate":"1994-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81734200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A means of compounding dextran 70 injection labeled with technetium Tc 99m by using readily available pharmaceutical components is described, and the compound's biological distribution is evaluated. The radiopharmaceutical was prepared by mixing 10 mg (0.17 mL) of dextran 70 in sodium chloride with 0.33 mL of 0.9% sodium chloride injection in a 1-mL syringe. This solution was added to a sterile, pyrogen-free vial containing stannous chloride, and the steps were repeated until five vials had been prepared. The contents of each vial were mixed by swirling until the solids were dissolved. The mixture was incubated for five minutes at 22 degrees C, then 1.48 gigabecquerels of sodium pertechnetate Tc 99m injection in a volume of 0.5 mL was added to each vial. The final mixture was incubated for 15 minutes at 22 degrees C and then stored at room temperature. Thin-layer chromatography was performed after zero, three, and six hours of storage to assess radiochemical purity. Five more vials were prepared as above, and five male volunteers were given 185 megabecquerels of the radiopharmaceutical by i.v. push, and scintigraphic images of the anterior chest were taken immediately and 1, 2, and 24 hours after injection. Immediately after preparation, a mean +/- S.D. of 99.0 +/- 1.0% of the 99mTc was bound to dextran 70. Mean +/- S.D. binding was 98.1 +/- 3.7% and 95.8 +/- 7.5% at three and six hours, respectively. Scintigraphy in the five volunteers yielded high-contrast images of the cardiac blood pool with little uptake of the radionuclide by the lungs. (ABSTRACT TRUNCATED AT 250 WORDS)
{"title":"Preparation of dextran 70 injection labeled with technetium 99m for use as a cardiac blood-pool imaging agent.","authors":"R. N. Dansereau, B. Line","doi":"10.1093/AJHP/51.22.2797","DOIUrl":"https://doi.org/10.1093/AJHP/51.22.2797","url":null,"abstract":"A means of compounding dextran 70 injection labeled with technetium Tc 99m by using readily available pharmaceutical components is described, and the compound's biological distribution is evaluated. The radiopharmaceutical was prepared by mixing 10 mg (0.17 mL) of dextran 70 in sodium chloride with 0.33 mL of 0.9% sodium chloride injection in a 1-mL syringe. This solution was added to a sterile, pyrogen-free vial containing stannous chloride, and the steps were repeated until five vials had been prepared. The contents of each vial were mixed by swirling until the solids were dissolved. The mixture was incubated for five minutes at 22 degrees C, then 1.48 gigabecquerels of sodium pertechnetate Tc 99m injection in a volume of 0.5 mL was added to each vial. The final mixture was incubated for 15 minutes at 22 degrees C and then stored at room temperature. Thin-layer chromatography was performed after zero, three, and six hours of storage to assess radiochemical purity. Five more vials were prepared as above, and five male volunteers were given 185 megabecquerels of the radiopharmaceutical by i.v. push, and scintigraphic images of the anterior chest were taken immediately and 1, 2, and 24 hours after injection. Immediately after preparation, a mean +/- S.D. of 99.0 +/- 1.0% of the 99mTc was bound to dextran 70. Mean +/- S.D. binding was 98.1 +/- 3.7% and 95.8 +/- 7.5% at three and six hours, respectively. Scintigraphy in the five volunteers yielded high-contrast images of the cardiac blood pool with little uptake of the radionuclide by the lungs. (ABSTRACT TRUNCATED AT 250 WORDS)","PeriodicalId":7452,"journal":{"name":"American journal of hospital pharmacy","volume":"42 1","pages":"2797-800"},"PeriodicalIF":0.0,"publicationDate":"1994-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84266724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号